Sysmex America, Inc.’s Post

🔍 Introducing Technetium Tc99m Sulfur Colloid Injection 🔍 Our Technetium Tc99m Sulfur Colloid Injection is designed for subcutaneous, intraperitoneal, intravenous, and oral diagnostic use. It aids in the localization of lymph nodes in breast cancer and melanoma, evaluates shunt patency, and supports imaging of the liver, spleen, and more. Why Choose Sulfur Colloid? ✅ Proven ✅ Trusted ✅ Safe Available by prescription only—consult your healthcare professional to see if it’s right for you. For detailed information, including indications, safety warnings, and usage, please refer to the full prescribing information. Your health and safety matter. Let’s ensure proper patient management with effective diagnostic tools. #Healthcare #Diagnostics #NuclearMedicine #PatientSafety LEVALIS PHARMA DMCC Pharmalucence

There is an excellent resource for Amyloidosis — the Video Journal of Hematology and Hematological Oncology at https://lnkd.in/eVV4aD7N “Reporting from key international congresses and speaking with world-leading experts, VJHemOnc brings you the latest exciting advances in amyloidosis research, diagnosis and care. The Amyloidosis Channel delivers regular video interviews, roundtable discussions, podcasts and feature articles, so that you can keep up-to-date with all the practice-changing developments in amyloidosis. Explore The Amyloidosis Channel to learn about the latest clinical trial updates, novel therapeutics and regimens, diagnostic advances and optimal management across all amyloidosis subtypes, including amyloid light chain (AL), amyloid A (AA), and transthyretin (ATTR) amyloidosis.” #meded #amyloidosis

There is an excellent resource on Amyloidosis — the Video Journal of Hematology and Hematological Oncology at https://lnkd.in/eVV4aD7N “Reporting from key international congresses and speaking with world-leading experts, VJHemOnc brings you the latest exciting advances in amyloidosis research, diagnosis and care. The Amyloidosis Channel delivers regular video interviews, roundtable discussions, podcasts and feature articles, so that you can keep up-to-date with all the practice-changing developments in amyloidosis. Explore The Amyloidosis Channel to learn about the latest clinical trial updates, novel therapeutics and regimens, diagnostic advances and optimal management across all amyloidosis subtypes, including amyloid light chain (AL), amyloid A (AA), and transthyretin (ATTR) amyloidosis.” #meded #amyloidosis

🌟 Fun Fact Friday 🌟 Did you know that Oxygen-18 in water plays a critical role in the production of ¹⁸F-FDG, the most widely used radiopharmaceutical in PET scans? This innovative tracer is vital for detecting cancer, as it mimics glucose and is absorbed by cells with high metabolic activity, such as tumors. When Oxygen-18 is bombarded with protons in a cyclotron, it transforms into Fluorine-18, which is then incorporated into ¹⁸F-FDG. This process allows healthcare professionals to visualize and evaluate metabolic activity throughout the body, enabling early diagnosis and effective monitoring of various cancers. By highlighting areas of increased metabolic activity, ¹⁸F-FDG provides essential insights into patient health and supports targeted treatment strategies. It’s fascinating how a simple isotope can make such a significant impact in modern medicine! 🩺💡 #InterskalaMedikaSolusindo #NuclearMedicine #FunFactFriday #Radiopharmaceuticals #CancerDetection #InnovationInHealthcare

Still wondering about #theranostics and the impact of this technology for patients? Theranostics, a groundbreaking fusion of "therapy" and "diagnostics," represents a revolutionary approach to personalized medicine. The combination of using one radiopharmaceutical to identify (diagnose) and a second radiopharmaceutical to deliver therapy to treat disease has provided a unique opportunity to craft highly-specific and targeted therapies with high efficacy and great clinical impact for patients. 👉 Learn more about theranostics: #nuclearmedicine  #radiopharmaceuticals #iqmedicalservices

#Diagnostic_Industry_101 I'm an 8-month newcomer to the diagnostics industry, and I want to share some of the observations and insights I've gained so far. One of the interesting things I’ve discovered since entering the diagnostics industry is how the market is divided into 'in vitro' and 'in vivo' diagnostics. 'In vitro' diagnostics involve samples taken outside the body—like blood, urine, and even poo!😅 Fun fact: the main products at my current company are rapid kits for colon cancer screening that use feces(=poo) samples. On the flip side, in vivo diagnostics involve looking directly inside the body, without taking anything out. Think X-rays, MRIs, and other imaging tests. It appears that these two markets have very different characteristics. I don’t see many companies focusing on both at the same time. And even if they do, the departments handling them are usually kept completely separate. It makes sense when you think about it: In vivo diagnostics need to be done where the patient is, and the equipment is often large and expensive—like MRI machines that hospitals typically lease rather than buy. In contrast, in vitro diagnostics are more flexible. Once a sample is taken, it doesn’t matter where the patient is at the time of testing. Plus, You can even run tests on multiple samples simultaneously. The analyzer can range from large machines to simple kits that don’t need any analyzer, like COVID-19 test kits. GE Healthcare and Siemens are prime examples of companies focused on in vivo diagnostics, while Roche, Abbott, and Thermo Fisher are well-known for their work in in vitro diagnostics. (Of course, this doesn't mean they don't work in other areas—it's just where their main focus lies!) If I’ve got anything wrong, please feel free to let me know!

We've supercharged our FFPE tissue inventory! Now boasting over 20,000 samples across 300 #cancer types, our expanded collection is ready to fuel #oncology research and medical breakthroughs. Why Choose Central BioHub’s FFPE Blocks? ·     Diverse Catalogue: Our collection includes a vast range of cancers, from the most prevalent to rare types, ensuring you have the specific samples needed for your research. ·     Unmatched Quality: Each block is preserved under standardized conditions, guaranteeing reliability for your complex analyses. ·     Versatility: Our samples cover benign, malignant, and primary tumors, supporting a wide range of studies from basic biology to therapeutic strategy testing. Find FFPE Block samples for your research on our website: ·     https://lnkd.in/e_4pBzEm #ResearchAndDevelopment #Biobanking #Diagnostics #Onlinemarketplace #DrugDiscovery #BiomedicalResearch #ClinicalResearch #IVD #Biotechnology #Healthcare #Pharma #Biomedicine

Yesterday we explained what Theranostics is, today we’re sharing fun facts. We narrowed our list to 4, but there are so many more. 1️⃣ Use of Theranostics began 80 years ago with Dr. Saul Hertz. 2️⃣ The debate over using Theranostics or Theragnostics rages on. Most leave out the “g”. 3️⃣ The concept of Theranostics is used to find and detect more than just cancer (Alzheimer’s Disease, Hyperthyroidism, Cardiac Disease, Parkinson’s). 4️⃣ Right now, 7 radiopharmaceutical treatments are FDA approved, but at least 80 radiopharmaceutical drugs are in development. Now want to hear from you! Add your fun Theranostics facts to the comments and let’s keep the conversation going. #Theranostics #WorldTheranosticsDay

Reminder to come by Plus Therapeutics at the SNMMI 2024 Annual Meeting in Toronto at Booth #1948 Learn about the latest ReSPECT-LM Clinical Trial data for Leptomeningeal Metastases and view our newest poster in the poster hall Two accepted abstracts titled: 1) "Rhenium (186Re) obisbemeda (186RNL) in leptomeningeal metastases (LM) Phase 1/2A Dose Escalation Trial: Update of Initial Safety and Feasibility through Cohorts 1-4" 2) "Radiation Absorbed Dose to Spinal Cord: Therapy of Leptomeningeal Metastasis Using Beta-Emission Radiopharmaceuticals" Posters will be available on https://lnkd.in/eQXB5zz5 after the conference. #SNMMI #BrainCancer #Glioblastoma #BreastCancer #LungCancer #Melanoma #ClinicalTrials 

I’m excited to share our latest article about analyzing aberrant #methylation pattern for circulating cell-free tumor DNA #ctDNA detection in #melanoma, that was just published in Clinical Chemistry, the leading journal of laboratory medicine and analytical chemistry: https://lnkd.in/eqJN56qz We prospectively assessed circulating cell-free SHOX2 DNA methylation levels and their dynamic changes in blood plasma of anti-PD-1 treated melanoma patients. Negativity of SHOX2 #ccfDNA methylation only 4 weeks after treatment initiation was strongly associated with improved survival.